High-Dose Oral Omeprazole Versus Continuous Intravenous Pantoprazole in Patients With High-Risk Peptic Ulcer Bleeding: A Single-Blinded Multicenter RCT.
J Gastroenterol HepatolJul 12, 2026 (epub)
Kanteera Sriyudthsak, Nutbordee Nalinthassanai, Bunyos Sriapiraksa et al.
✦ AI-curated · Sources linked
In 30 seconds
This multicenter randomized controlled trial compared high-dose oral omeprazole to continuous intravenous pantoprazole in 124 patients with high-risk peptic ulcer bleeding post-endoscopy. The study found that 72-hour rebleeding occurred in 1.6% of the omeprazole group versus 4.8% in the pantoprazole group, indicating a potential advantage for oral omeprazole.
Key findings
- 72-hour rebleeding rates were 1.6% for oral omeprazole versus 4.8% for IV pantoprazole.
- 30-day rebleeding rates were 3.3% for omeprazole and 4.8% for pantoprazole.
- The median percentage of gastric pH > 6 was 56.3% in the oral group compared to 27.3% in the IV group.
Why it matters
Understanding the efficacy of oral omeprazole versus IV pantoprazole can guide treatment decisions in managing peptic ulcer bleeding, potentially improving patient outcomes and resource utilization.